Compare · ABBV vs PRQR
ABBV vs PRQR
Side-by-side comparison of AbbVie Inc. (ABBV) and ProQR Therapeutics N.V. (PRQR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PRQR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $458.24B, about 1887.8x PRQR ($242.7M).
- Over the past year, ABBV is up 37.6% and PRQR is down 23.4% - ABBV leads by 60.9 points.
- PRQR has been more active in the news (7 items in the past 4 weeks vs 5 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 18 for PRQR).
- Company
- AbbVie Inc.
- ProQR Therapeutics N.V.
- Price
- $259.26+0.91%
- $1.72-3.91%
- Market cap
- $458.24B
- $242.7M
- 1M return
- +10.36%
- -4.97%
- 1Y return
- +37.55%
- -23.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2014
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 18
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest PRQR
- Amendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.
- Director Filius Bart bought $257,925 worth of Ordinary Shares (150,000 units at $1.72), increasing direct ownership by 100% to 300,000 units (SEC Form 4)
- SEC Form EFFECT filed by ProQR Therapeutics N.V.
- SEC Form 424B5 filed by ProQR Therapeutics N.V.
- Chief Executive Officer De Boer Daniel Anton bought $261,000 worth of Ordinary Shares (150,000 units at $1.74), increasing direct ownership by 100% to 300,000 units (SEC Form 4)
- Chief Executive Officer De Boer Daniel Anton bought $238,500 worth of Ordinary Shares (150,000 units at $1.59) (SEC Form 4)
- SEC Form F-3 filed by ProQR Therapeutics N.V.
- Amendment: SEC Form 4 filed by Director Hinsch Gylvin Lykke
- Director Filius Bart bought $231,000 worth of Ordinary Shares (150,000 units at $1.54) (SEC Form 4)
- SEC Form 6-K filed by ProQR Therapeutics N.V.